Drug Trial Radar · NCT04802746
A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma
Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Mar 9, 2021
Primary completion
Nov 22, 2021
Study completion Nov 22, 2021
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the pulmonary safety of Staccato alprazolam in healthy study participants and in and study participants with mild asthma
Conditions
- Healthy Study Participants
- Participants With Mild Asthma
Interventions
AlprazolamDrug
Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
PlaceboOther
Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 1 in Part ATime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 1)
- Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 4 in Part ATime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 4)
- Percentage of study participants with respiratory treatment-emergent adverse events (TEAEs) in Part ATime frame: From Baseline (Day 1) to Safety Follow-up period (up to Day 44)
- Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 1 in Part BTime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 1)
- Change from Baseline in Forced Expiratory Volume in 1 second (FEV1) to 6 hours postdose on Day 4 in Part BTime frame: From Baseline (predose Day 1) to 6 hours postdose (Day 4)
- Percentage of study participants with respiratory treatment-emergent adverse events (TEAEs) in Part BTime frame: From Baseline (Day 1) to Safety Follow-up period (up to Day 14)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Up0099 101
North Dartmouth, Massachusetts
Up0099 102
Raleigh, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.